Eli Lilly
AI Intelligence Briefcase
Synthesize all available public data, government contracts, patent filings, and funding rounds for Eli Lilly into a comprehensive strategic report.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No recent patents found.
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Eli Lilly, Space Command help lead Alabama to Silver Shovel Award
Alabama earns Silver Shovel Award after Space Command, Eli Lilly investments
Governor Ivey Announces Eli Lilly, Space Command and Other State Economic Growth Help Earn Alabama a Silver Shovel Award - Alabama Governor's Office (.gov)
Eli Lilly, Space Command and other growth help earn Alabama a Silver Shovel Award
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
Eli Lilly Stock's Trillion-Dollar Question
Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.
Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain
Novo Nordisk has lost GLP-1 leadership against Eli Lilly. Click here to read more about NVO stock and why it is a Hold.
Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market?
Eli Lilly and Co (NYSE:LLY) is one of billionaire Ken Fisher’s top high growth stock picks. In the past month, Lilly shares have gained more than 18%. The shares have soared almost 50% over the past year. On June 6, Eli Lilly and Co (NYSE:LLY) presented results from late-stage trials of its weight-loss drug candidate, […]
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro